Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
Type:
Grant
Filed:
January 30, 2023
Date of Patent:
October 8, 2024
Assignee:
LAVA THERAPEUTICS N.V.
Inventors:
Johannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris
Abstract: The present invention relates to novel methods for the treatment of hematological malignancies. In particular, the invention relates to the treatment of hematological malignancies using antibodies comprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human V?9V?2-TCR.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
September 3, 2024
Assignee:
LAVA THERAPEUTICS N.V.
Inventors:
Iris De Weerdt, Arnon Philip Kater, Paul Willem Henri Ida Parren, Tanja Denise De Gruijl, Johannes Jelle Van Der Vliet, Roeland Lameris
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
February 28, 2023
Assignee:
LAVA THERAPEUTICS N.V.
Inventors:
Johannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris
Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human V?9V?2 T cell receptor binding immunoglobulin molecules. Human V?9V?2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human V?9V?2 T cells, wherein human V?9V?2 T cells may be modulated.
Type:
Grant
Filed:
October 28, 2021
Date of Patent:
July 12, 2022
Assignee:
LAVA THERAPEUTICS N.V.
Inventors:
Johannes Jelle Van Der Vliet, Renée Cornelia Gerarda De Bruin, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul
Abstract: A guitar includes fibers of lengths between 0.2 millimeters to 3 millimeters. The guitar further includes a guitar body, a headstock board, a soundboard, a fretboard, and a guitar bridge. Each of the guitar body, the headstock board, the soundboard, the fretboard, and the guitar bridge is a continuous and single structure. The disclosure also relates to a guitar and a method for manufacturing a guitar. The guitar is superior to the traditional acoustic guitars in terms of volume and mechanical performance, so that a service life of the guitar of the application can be increased by 2 to 3 times compared with traditional acoustic guitars and durable.
Abstract: A method for producing a double jersey fabric on a double jersey, single jacquard circular knitting machine includes steps of knitting a front side of the fabric on a cylinder (C) and knitting the rear side of the fabric on a dial (D) of the machine, knitting a base yarn on a rear side of the fabric, except for connecting points where the base yarn is knitted on the front side of the fabric. The method additionally includes steps of inserting a pattern yarn before a start of a pattern unit, which is produced using the pattern yarn, knitting the pattern yarn on the front side of the fabric in the pattern unit and cutting off the pattern yarn after the pattern unit.
Abstract: There is described a packaging apparatus (1) for forming sealed packages (2) from a tube (3). The packaging apparatus (1) has an endless conveyor device (7) arranged in a conveyor zone (8), conveying carts (9) and operative units (10, 10?) moved by the plurality of conveying carts (9) along a path (P, Q). Each operative unit (10, 10?) moves between an operative configuration, in which the operative unit (10, 10?) manipulates the tube (3) and a rest configuration in which the operative unit (10, 10?) is detached from the tube (3). Each operative unit (10, 10?) has a half-shell (36) and one of a sealing element (37a) or a counter-sealing element (37b) and each operative unit (10, 10?) is carried by one respective conveying cart (9) and extends laterally away therefrom so that the conveyor zone (8) is laterally spaced apart from an operative zone (33) where the tube is manipulated.
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
Type:
Grant
Filed:
January 27, 2016
Date of Patent:
December 10, 2019
Assignee:
LAVA THERAPEUTICS B.V.
Inventors:
Johannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris
Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human V?9V?2 T cell receptor binding immunoglobulin molecules. Human V?9V?2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human V?9V?2 T cells, wherein human V?9V?2 T cells may be modulated.
Type:
Grant
Filed:
April 10, 2015
Date of Patent:
December 10, 2019
Assignee:
LAVA Therapeutics B.V.
Inventors:
Johannes Jelle Van Der Vliet, Renée Cornelia Gerarda De Bruin, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul
Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human V?9V?2 T cell receptor binding immunoglobulin molecules.
Type:
Application
Filed:
May 16, 2019
Publication date:
August 29, 2019
Applicant:
LAVA THERAPEUTICS B.V.
Inventors:
Johannes Jelle VAN DER VLIET, Renée Marinus Willem VERHEUL